LLY vs REGN
By Alex · Tickerpine
Eli Lilly and Company vs Regeneron Pharmaceuticals, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | REGN |
|---|---|---|
| Price | $1,443.50 | $955.47 |
| Market cap | $1.29T | $98.84B |
| P/E ratio | 46.9 | 21.1 |
| ROE | 86.02% | 14.95% |
| Profit margin | 31.90% | 28.51% |
| Revenue growth | 38.60% | 36.30% |
| Dividend yield | 0.48% | 0.39% |
| Beta | 0.39 | 0.10 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs REGN in plain English
- LLY is the bigger company — about 13.0× the market cap of REGN.
- REGN is cheaper on earnings (P/E 21.1 vs 46.9).
- LLY earns a higher return on equity (86% vs 15%).
- LLY is growing revenue faster (39% vs 36%).
- LLY has the higher dividend yield (0.48% vs 0.39%).
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
REGN return calculator
See what $1,000 in Regeneron Pharmaceuticals, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.